Abstract:Purpose: Dry eye is commonly associated with autoimmune diseases such as Sjögren's syndrome (SS), in which exocrinopathy of the lacrimal gland leads to aqueous tear deficiency and keratoconjunctivitis sicca (KCS). KCS is among the most common and debilitating clinical manifestations of SS that is often recalcitrant to therapy. We established mice deficient in the autoimmune regulator (Aire) gene as a model for autoimmune-mediated aqueous-deficient dry eye. In Aire-deficient mice, CD4+ T cells represent the main effector cells and local signaling via the interleukin-1 (IL-1/IL-1R1) pathway provides an essential link between autoreactive CD4+ T cells and ocular surface disease. In the current study, we evaluated the efficacy of topical administration of IL-1R1 antagonist (IL-1RA) anakinra in alleviating ocular surface damage resulting from aqueous-deficient dry eye in the setting of autoimmune disease. Methods: We compared the effect of commercially available IL-1R1 antagonist, anakinra (50 μg/mL concentration) to that of carboxymethylcellulose (CMC) vehicle control as a treatment for dry eye. Age-matched, Aire-deficient mice were treated three times daily with anakinra or CMC vehicle for 14 days using side-by-side (n = 4 mice/group) and paired-eye (n = 5) comparisons. We assessed (1) ocular surface damage with lissamine green staining; (2) tear secretion with wetting of phenol-red threads; (3) goblet cell (GC) mucin glycosylation with lectin histochemistry; (4) immune cell infiltration using anti-F4/80, CD11c, and CD4 T cell antibodies; and (5) gene expression of cornified envelope protein, Small Proline-Rich Protein-1B (SPRR1B) with real-time quantitative polymerase chain reaction. Results: Aire-deficient mice treated with anakinra experienced significant improvements in ocular surface integrity and tear secretion. After 7 days of treatment, lissamine green staining decreased in eyes treated with anakinra compared to an equivalent increase in staining following treatment with CMC vehicle alone. By day 14, lissamine green staining in anakinra-treated eyes remained stable while eyes treated with CMC vehicle continued to worsen. Accordingly, there was a progressive decline in tear secretion in eyes treated with the CMC vehicle compared to a progressive increase in the anakinra-treated eyes over the 2-week treatment period. Aberrant acidification of GC mucins and pathological keratinization of the ocular surface were significantly reduced in anakinra-treated eyes. Significantly fewer Maackia amurensis leukoagglutinin positive goblet cells were noted in the conjunctiva of anakinra-treated eyes with a corresponding decrease in the expression of the pathological keratinization marker, SPRR1B. Finally, there was a downward trend in the infiltration of each immune cell type following anakinra treatment, but the cell counts compared to eyes treated with the vehicle alone were not significantly different. Conclusions: IL-1R antagonist, anakinra, demonstrates therapeutic benefits as a topical treatment for aqueous-deficient dry eye in a spontaneous mouse model of autoimmune KCS that mimics the clinical characteristics of SS. Targeting the IL-1/IL-1R1 signaling pathway through topical administration of IL-1RA may provide a novel option to improve ocular surface integrity, increase tear secretion, and restore the normal glycosylation pattern of GC mucins in patients with SS.

Topical Application of Interleukin-28A Attenuates Allergic Conjunctivitis in an Ovalbumin-Induced Mouse Model.

Quercetin as a Lyn kinase inhibitor inhibits IgE-mediated allergic conjunctivitis

Interleukin-22 attenuates allergic airway inflammation in ovalbumin-induced asthma mouse model

Intranasal Administration of IL-27 Pre-OVA Sensitization Alleviate Allergic Airway Inflammation in Mice Model

Reduced Serum Antibody Production and Acute Airway Inflammation in Interleukin 6-deficient Mice Challenged with Ovalbumin

[The role and its regulatory significance of interleukin-25 in ovalbumin induced atopic dermatitis of mice]

The effects of neutralizing anti-murine interleukin-17A monoclonal antibody on ozone-induced inflammation and glucocorticoids insensitivity in a murine model of asthma

Involvement of the annexin A1-Fpr anti-inflammatory system in the ocular allergy

Alleviating Experimental Allergic Eye Disease by Inhibiting Pro-Lymphangiogenic VEGFR3 Signal

TRPV1+ Sensory Nerves Suppress Conjunctival Inflammation Via SST-SSTR5 Signaling in Murine Allergic Conjunctivitis.

Interleukin-17 Orchestrates the Granulocyte Influx into Airways after Allergen Inhalation in A Mouse Model of Allergic Asthma

Effects of Ozone Repeated Short Exposures on the Airway/lung Inflammation, Airway Hyperresponsiveness and Mucus Production in a Mouse Model of Ovalbumin-Induced Asthma.

The role of interleukin-22 in the treatment of allergic rhinitis of mice

Therapeutic effect of topical administration with CpG ODN for allergic conjunctivitis

IL-33/ST2/IL-9/IL-9R signaling disrupts ocular surface barrier in allergic inflammation

Therapeutic Potential of Combined Anti-Il-1β IgY and Anti-Tnf-α IgY in Guinea Pigs with Allergic Rhinitis Induced by Ovalbumin.

Exclusion of Il-21 in the Pathogenesis of Ova-Induced Asthma in Mice

Apigenin Attenuates Allergic Responses of Ovalbumin-Induced Allergic Rhinitis Through Modulation of Th1/Th2 Responses in Experimental Mice

The effects of resiquimod in an ovalbumin-induced allergic rhinitis model

Interleukin-16 Aggravates Ovalbumin-Induced Allergic Inflammation by Enhancing Th2 and Th17 Cytokine Production in a Mouse Model

Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease